X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2025-11-17 | ANNX | Annexon, Inc. | Satter Muneer A | Dir | P - Purchase | $3.37 | +1,500,000 | 8,906,024 | +20% | +$5,055,000 | |||||
| M | 2025-11-17 | ALMS | Alumis Inc. | Foresite Labs, LLC | 10% | P - Purchase | $6.09 | +507,874 | 15,705,828 | +3% | +$3,094,725 | |||||
| M | 2025-11-17 | ALMS | Alumis Inc. | Foresite Capital Management VI LLC | 10% | P - Purchase | $6.09 | +507,874 | 15,705,828 | +3% | +$3,094,725 | |||||
| M | 2025-11-17 | ALMS | Alumis Inc. | Tananbaum James B. | Dir, 10% | P - Purchase | $6.09 | +507,874 | 15,705,828 | +3% | +$3,094,725 | |||||
| M | 2025-11-17 | ALMS | Alumis Inc. | Akkaraju Srinivas | Dir | P - Purchase | $6.34 | +241,338 | 5,009,248 | +5% | +$1,529,865 | |||||
| M | 2025-11-17 | SION | Sionna Therapeutics, Inc. | Ra Capital Management, L.P. | Dir, 10% | S - Sale | $40.34 | -136,351 | 168,193 | -45% | -$5,500,158 | |||||
2025-11-17 | JAZZ | Jazz Pharmaceuticals Plc | Iannone Robert | EVP, Global Head of R, D, CMO | S - Sale | $168.26 | -7,159 | 72,628 | -9% | -$1,204,573 | ||||||
| M | 2025-11-18 | TYRA | Tyra Biosciences, Inc. | Bensen Daniel | COO | S - Sale | $16.17 | -125,589 | 170,981 | -42% | -$2,030,923 | |||||
2025-11-17 | TENX | Tenax Therapeutics, Inc. | McGauley Thomas | Interim CFO | P - Purchase | $7.27 | +8,000 | 8,000 | New | +$58,164 | ||||||
2025-11-19 | CYTK | Cytokinetics Inc | Parshall B Lynne | Dir | S - Sale | $64.73 | -5,000 | 22,933 | -18% | -$323,650 | ||||||
2025-11-17 | ELVN | Enliven Therapeutics, Inc. | Kintz Samuel | Pres, CEO | S - Sale | $21.82 | -12,500 | 890,392 | -1% | -$272,739 | ||||||
| DM | 2025-11-17 | TENX | Tenax Therapeutics, Inc. | Almenoff June Sherie | Dir | P - Purchase | $7.50 | +1,993 | 1,993 | New | +$14,945 | |||||
2025-11-12 | NATR | Natures Sunshine Products Inc | Norman Daniel C | EVP, Pres, Asia | S - Sale | $20.46 | -8,884 | 63,065 | -12% | -$181,767 | ||||||
| D | 2025-11-18 | ACAD | Acadia Pharmaceuticals Inc | Schneyer Mark C. | EVP, CFO | S - Sale+OE | $23.69 | -10,262 | 53,338 | -16% | -$243,114 | |||||
| D | 2025-11-18 | ACAD | Acadia Pharmaceuticals Inc | Kihara James | PRINCIPAL ACCOUNTING OFFICER | S - Sale+OE | $23.69 | -4,084 | 25,058 | -14% | -$96,754 | |||||
2025-11-18 | NATR | Natures Sunshine Products Inc | Lanoy Jonathan David | SVP, Chief Accounting Officer | S - Sale | $20.45 | -5,000 | 46,233 | -10% | -$102,250 | ||||||
| D | 2025-11-17 | PTCT | Ptc Therapeutics, Inc. | Boulding Mark Elliott | EVP, CLO | S - Sale+OE | $75.99 | -2,812 | 103,901 | -3% | -$213,687 | |||||
| DM | 2025-11-17 | NUVL | Nuvalent, Inc. | Balcom Alexandra | CFO | S - Sale+OE | $99.62 | -20,729 | 61,734 | -25% | -$2,065,030 | |||||
| D | 2025-11-17 | NUVL | Nuvalent, Inc. | Miller Deborah Ann | GC | S - Sale+OE | $105.50 | -24,200 | 49,086 | -33% | -$2,552,999 | |||||
| M | 2025-11-17 | BBIO | Bridgebio Pharma, Inc. | Lo Andrew | Dir | S - Sale | $66.11 | -95,599 | 64,672 | -60% | -$6,319,662 | |||||
| D | 2025-11-17 | BBIO | Bridgebio Pharma, Inc. | Scott Randal W. | Dir | S - Sale+OE | $66.65 | -10,000 | 15,589 | -39% | -$666,465 | |||||
2025-11-19 | OPK | Opko Health, Inc. | Frost Phillip Md Et Al | CEO, COB, 10% | P - Purchase | $1.31 | +580,000 | 249,242,576 | 0% | +$759,115 | ||||||
2025-11-17 | ONC | Beone Medicines Ltd. | Wu Xiaobin | Pres, COO | S - Sale | $380.43 | -3,991 | 985,343 | 0% | -$1,518,303 | ||||||
2025-11-17 | RPRX | Royalty Pharma Plc | Coyne Terrance P. | EVP, CFO | S - Sale | $39.30 | -69,594 | 829,306 | -8% | -$2,735,329 | ||||||
| DM | 2025-11-17 | NUVB | Nuvation Bio Inc. | Liu Dongfang | CHIEF MEDICAL OFFICER | S - Sale+OE | $4.93 | -30,000 | 18,000 | -63% | -$148,028 | |||||
| M | 2025-11-17 | RCUS | Arcus Biosciences, Inc. | Jaen Juan C. | Pres | S - Sale | $20.26 | -50,000 | 1,404,280 | -3% | -$1,012,764 | |||||
| D | 2025-11-17 | KNSA | Kiniksa Pharmaceuticals International, Plc | Tessari Eben | COO | S - Sale+OE | $41.24 | -12,470 | 22,714 | -35% | -$514,224 | |||||
2025-11-17 | PCRX | Pacira Biosciences, Inc. | Slonin Jonathan | Chief Medical Officer | S - Sale | $24.09 | -3,960 | 178,367 | -2% | -$95,396 | ||||||
2025-11-17 | AMRX | Amneal Pharmaceuticals, Inc. | Nark Ted C | Dir | S - Sale | $11.72 | -50,000 | 291,029 | -15% | -$586,000 | ||||||
| D | 2025-11-18 | KALV | Kalvista Pharmaceuticals, Inc. | Palleiko Benjamin L | CEO | S - Sale+OE | $14.48 | -4,466 | 403,879 | -1% | -$64,665 | |||||
| D | 2025-11-18 | KALV | Kalvista Pharmaceuticals, Inc. | Yea Christopher | CHIEF DEVELOPMENT OFFICER | S - Sale+OE | $14.48 | -2,683 | 133,574 | -2% | -$38,848 | |||||
| D | 2025-11-18 | KALV | Kalvista Pharmaceuticals, Inc. | Audhya Paul K. | CHIEF MEDICAL OFFICER | S - Sale+OE | $14.48 | -3,075 | 125,877 | -2% | -$44,524 | |||||
2025-11-17 | VRTX | Vertex Pharmaceuticals Inc / Ma | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Offi | S - Sale | $434.58 | -2,500 | 16,852 | -13% | -$1,086,450 | ||||||
2025-11-17 | CYPH | Cypherpunk Technologies Inc. | Mirabelli Christopher | Dir | S - Sale | $3.14 | -676,319 | 23,050 | -97% | -$2,123,642 | ||||||
2025-11-17 | CYPH | Cypherpunk Technologies Inc. | Cavanaugh James H | Dir | S - Sale | $3.14 | -261,840 | 213 | -100% | -$822,178 | ||||||
| D | 2025-11-17 | ALNY | Alnylam Pharmaceuticals, Inc. | Fitzgerald Kevin Joseph | CSO, EVP, Head of Research | S - Sale+OE | $452.18 | -12,128 | 21,801 | -36% | -$5,483,990 | |||||
2025-11-17 | CYPH | Cypherpunk Technologies Inc. | Onsi Douglas E | CEO,CFO,Pres,GC,Treas., Sec. | S - Sale | $3.14 | -676,319 | 108,282 | -86% | -$2,123,642 | ||||||
2025-11-17 | IRWD | Ironwood Pharmaceuticals Inc | Gaskins Tammi L | Chief Commercial Officer | S - Sale | $3.32 | -6,016 | 235,264 | -2% | -$19,973 | ||||||
| DM | 2025-11-17 | GALT | Galectin Therapeutics Inc | Lewis Joel | Pres, CEO | S - Sale+OE | $6.07 | -22,463 | 834,592 | -3% | -$136,366 | |||||
2025-11-17 | PTGX | Protagonist Therapeutics, Inc | Molina Arturo Md | Chief Medical Officer | S - Sale | $84.77 | -2,712 | 81,180 | -3% | -$229,896 | ||||||
| DM | 2025-11-17 | GALT | Galectin Therapeutics Inc | Callicutt Jack W | CFO | S - Sale+OE | $6.15 | -77,920 | 7,614 | -91% | -$478,849 | |||||
| E | 2025-11-18 | LLY | Eli Lilly & Co | Lilly Endowment Inc | 10% | S - Sale | $0.17 | -60,213 | 92,811,978 | 0% | -$10,350 | |||||
| D | 2025-11-18 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Chief Scientific Officer | S - Sale+OE | $3.75 | -6,500 | 0 | -100% | -$24,402 | |||||
2025-11-18 | PHIO | Phio Pharmaceuticals Corp. | Bitterman Robert J | COB, Pres, CEO | P - Purchase | $1.27 | +5,000 | 276,421 | +2% | +$6,350 | ||||||
| M | 2025-11-17 | CRVO | Cervomed Inc. | Winton Matthew | Chief Commercial, Business | P - Purchase | $8.29 | +5,000 | 15,000 | +50% | +$41,430 | |||||
2025-11-17 | CRVO | Cervomed Inc. | Gregoire Sylvie | Dir, 10% | P - Purchase | $8.46 | +21,600 | 1,496,578 | +1% | +$182,736 | ||||||
| M | 2025-11-17 | CRVO | Cervomed Inc. | Elder William Robert | CFO, GC, Secretary | P - Purchase | $8.36 | +3,500 | 12,500 | +39% | +$29,250 | |||||
2025-11-17 | CRVO | Cervomed Inc. | Alam John J | CEO, Pres, 10% | P - Purchase | $8.46 | +21,600 | 1,496,578 | +1% | +$182,736 | ||||||
2025-11-14 | CRMD | Cormedix Inc. | Dillione Janet | Dir | S - Sale | $11.42 | -30,000 | 48,473 | -38% | -$342,600 | ||||||
| DM | 2025-11-17 | PAHC | Phibro Animal Health Corp | Bendheim Jack | Pres, CEO, 10% | S - Sale+OE | $44.19 | -10,560 | 66,520 | -14% | -$466,631 | |||||
2025-11-17 | BBIO | Bridgebio Pharma, Inc. | Trimarchi Thomas | Pres, CFO | S - Sale | $66.46 | -16,934 | 382,830 | -4% | -$1,125,404 | ||||||
| D | 2025-11-17 | DAWN | Day One Biopharmaceuticals, Inc. | Dubow Adam | GC, Secretary | S - Sale+OE | $8.91 | -4,319 | 62,626 | -6% | -$38,503 | |||||
| D | 2025-11-17 | DAWN | Day One Biopharmaceuticals, Inc. | York Charles N II | COO, CFO | S - Sale+OE | $8.91 | -4,062 | 294,715 | -1% | -$36,212 | |||||
| D | 2025-11-17 | DAWN | Day One Biopharmaceuticals, Inc. | Merendino Lauren | Chief Commercial Officer | S - Sale+OE | $8.91 | -3,726 | 50,809 | -7% | -$33,216 | |||||
| D | 2025-11-17 | DAWN | Day One Biopharmaceuticals, Inc. | Bender Jeremy | CEO | S - Sale+OE | $8.91 | -15,894 | 1,786,003 | -1% | -$141,690 | |||||
2025-11-14 | NATR | Natures Sunshine Products Inc | Brower Nathan G | EVP, GC | S - Sale | $20.81 | -3,800 | 46,735 | -8% | -$79,078 | ||||||
2025-11-14 | RNTX | Rein Therapeutics, Inc. | Voss Capital, LP | 10% | P - Purchase | $1.22 | +104,183 | 1,426,441 | +8% | +$127,593 | ||||||
2025-11-18 | OPK | Opko Health, Inc. | Frost Phillip Md Et Al | CEO, COB, 10% | P - Purchase | $1.27 | +533,300 | 248,662,576 | 0% | +$678,906 | ||||||
| D | 2025-11-17 | UTHR | United Therapeutics Corp | Benkowitz Michael | Pres, COO | S - Sale+OE | $470.43 | -22,500 | 2,648 | -89% | -$10,584,756 | |||||
2025-11-14 | TRDA | Entrada Therapeutics, Inc. | Parmar Kush | Dir, 10% | S - Sale | $8.80 | -200,000 | 4,056,379 | -5% | -$1,760,000 | ||||||
| D | 2025-11-17 | UTHR | United Therapeutics Corp | Edgemond James | CFO, TREASURER | S - Sale+OE | $470.36 | -21,000 | 8,118 | -72% | -$9,877,535 | |||||
| DM | 2025-11-14 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $465.25 | -8,000 | 644,489 | -1% | -$3,721,967 | |||||
2025-11-14 | TRDA | Entrada Therapeutics, Inc. | 5Am Ventures V, L.P. | 10% | S - Sale | $8.80 | -200,000 | 4,056,379 | -5% | -$1,760,000 | ||||||
| D | 2025-11-15 | MCRB | Seres Therapeutics, Inc. | Young Teresa L. | See Remarks | S - Sale+OE | $17.30 | -1,042 | 8,401 | -11% | -$18,027 | |||||
| D | 2025-11-15 | MCRB | Seres Therapeutics, Inc. | Shaff Eric D. | Dir | S - Sale+OE | $17.30 | -217 | 11,113 | -2% | -$3,754 | |||||
| D | 2025-11-15 | MCRB | Seres Therapeutics, Inc. | Desrosier Thomas | See Remarks | S - Sale+OE | $17.30 | -76 | 7,623 | -1% | -$1,315 | |||||
| D | 2025-11-15 | MCRB | Seres Therapeutics, Inc. | Henn Matthew R | See Remarks | S - Sale+OE | $17.30 | -1,257 | 7,527 | -14% | -$21,746 | |||||
2025-11-17 | RAPP | Rapport Therapeutics, Inc. | Ceesay Abraham | CEO | S - Sale | $25.20 | -10,916 | 691,453 | -2% | -$275,047 | ||||||
2025-11-18 | RMTI | Rockwell Medical, Inc. | Cooper John G | Dir | S - Sale | $0.87 | -5,079 | 140,372 | -3% | -$4,419 | ||||||
2025-11-17 | RAPP | Rapport Therapeutics, Inc. | Bredt David | Chief Scientific Officer | S - Sale | $25.19 | -8,500 | 401,142 | -2% | -$214,091 | ||||||
| D | 2025-11-18 | CYTK | Cytokinetics Inc | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $66.45 | -2,200 | 140,610 | -2% | -$146,190 | |||||
2025-11-14 | STOK | Stoke Therapeutics, Inc. | Krainer Adrian R. | Dir | S - Sale | $26.98 | -40,472 | 364,246 | -10% | -$1,092,058 | ||||||
2025-11-17 | INSM | Insmed Inc | Lee Leo | Dir | S - Sale | $195.90 | -75,000 | 54,677 | -58% | -$14,692,249 | ||||||
2025-11-14 | INSM | Insmed Inc | Anderson Elizabeth M | Dir | S - Sale | $195.87 | -10,000 | 63,729 | -14% | -$1,958,700 | ||||||
| D | 2025-11-17 | CNTA | Centessa Pharmaceuticals Plc | Hussain Iqbal J | GC | S - Sale+OE | $27.64 | -6,000 | 105,386 | -5% | -$165,835 | |||||
| D | 2025-11-17 | CNTA | Centessa Pharmaceuticals Plc | Bush Tia L | Chief Technology, Quality Ofc | S - Sale+OE | $28.00 | -40,000 | 121,503 | -25% | -$1,120,000 | |||||
2025-11-18 | BIXT | Bioxytran, Inc | Hoberman Alan M | Dir | P - Purchase | $0.60 | +210,000 | 626,207 | +50% | +$126,000 | ||||||
2025-11-14 | TEVA | Teva Pharmaceutical Industries Ltd | Fox Christine | EVP, Head of U.S. Commercial | S - Sale | $25.11 | -30,000 | 28,384 | -51% | -$753,321 | ||||||
| E | 2025-11-17 | LLY | Eli Lilly & Co | Lilly Endowment Inc | 10% | S - Sale | $0.21 | -9,886 | 92,872,191 | 0% | -$2,062 | |||||
2025-11-17 | APLS | Apellis Pharmaceuticals, Inc. | Watson David O. | GC | S - Sale | $20.06 | -5,000 | 168,866 | -3% | -$100,300 | ||||||
2025-11-14 | ANVS | Annovis Bio, Inc. | Hoffman Michael B | Dir | P - Purchase | $2.11 | +15,000 | 2,693,896 | +1% | +$31,650 | ||||||
2025-11-17 | BHVN | Biohaven Ltd. | Clark George C. | VP, Chief Accounting Officer | P - Purchase | $8.52 | +17,000 | 85,595 | +25% | +$144,770 | ||||||
2025-11-17 | TTRX | Turn Therapeutics Inc. | Chaudhary Zuraiz | See Remarks | P - Purchase | $3.62 | +2,500 | 7,550 | +50% | +$9,050 | ||||||
| D | 2025-11-13 | ARQT | Arcutis Biotherapeutics, Inc. | Krishnamohan Neha | Dir | S - Sale+OE | $23.20 | -40,504 | 22,123 | -65% | -$939,494 | |||||
| M | 2025-11-13 | HOWL | Werewolf Therapeutics, Inc. | Evnin Luke | Dir | S - Sale | $0.96 | -134,553 | 3,515,880 | -4% | -$128,785 | |||||
| M | 2025-11-13 | HOWL | Werewolf Therapeutics, Inc. | Mpm Bioventures 2014, L.P. | 10% | S - Sale | $0.96 | -209,652 | 5,481,539 | -4% | -$200,665 | |||||
| M | 2025-11-13 | HOWL | Werewolf Therapeutics, Inc. | Gadicke Ansbert | 10% | S - Sale | $0.96 | -209,652 | 5,481,539 | -4% | -$200,665 | |||||
| M | 2025-11-13 | TYRA | Tyra Biosciences, Inc. | Bensen Daniel | COO | S - Sale | $16.04 | -131,411 | 296,570 | -31% | -$2,108,067 | |||||
2025-11-13 | ANIP | Ani Pharmaceuticals Inc | Walsh Patrick D | Dir | S - Sale | $86.88 | -8,643 | 58,405 | -13% | -$750,904 | ||||||
| D | 2025-11-13 | XERS | Xeris Biopharma Holdings, Inc. | Shannon John Patrick Jr | See Remarks | S - Sale+OE | $7.46 | -23,242 | 2,730,253 | -1% | -$173,402 | |||||
| M | 2025-11-13 | ROIV | Roivant Sciences Ltd. | Ramaswamy Vivek | 10% | S - Sale | $20.46 | -1,854,603 | 47,011,613 | -4% | -$37,939,112 | |||||
2025-11-13 | ALMS | Alumis Inc. | Akkaraju Srinivas | Dir | P - Purchase | $5.25 | +276,179 | 4,767,910 | +6% | +$1,449,940 | ||||||
2025-11-13 | MRVI | Maravai Lifesciences Holdings, Inc. | Brust Bernd | CEO | P - Purchase | $3.25 | +216,212 | 2,466,771 | +10% | +$702,689 | ||||||
| M | 2025-11-13 | FGEN | Fibrogen Inc | Wettig Thane | CEO | P - Purchase | $9.12 | +3,700 | 24,979 | +17% | +$33,750 | |||||
| D | 2025-11-13 | AMPH | Amphastar Pharmaceuticals, Inc. | Petersen Floyd F. | Dir | S - Sale+OE | $26.49 | -16,679 | 75,531 | -18% | -$441,837 | |||||
| DM | 2025-11-13 | VRTX | Vertex Pharmaceuticals Inc / Ma | Leiden Jeffrey M | Exec COB | S - Sale+OE | $440.60 | -73,292 | 24,466 | -75% | -$32,292,320 | |||||
| D | 2025-11-14 | AVTX | Avalo Therapeutics, Inc. | Goldman Jonathan | Dir | S - Sale+OE | $14.33 | -11,367 | 0 | -100% | -$162,937 | |||||
| E | 2025-11-14 | LLY | Eli Lilly & Co | Lilly Endowment Inc | 10% | S - Sale | $11.59 | -178,295 | 92,882,077 | 0% | -$2,065,796 | |||||
| M | 2025-11-13 | CRVO | Cervomed Inc. | Gregoire Sylvie | Dir, 10% | P - Purchase | $7.53 | +7,847 | 1,474,978 | +1% | +$59,101 | |||||
| M | 2025-11-13 | CRVO | Cervomed Inc. | Alam John J | CEO, Pres, 10% | P - Purchase | $7.53 | +7,847 | 1,474,978 | +1% | +$59,101 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |